Trial Profile

Evaluating the Safety, Tolerability, and Pharmacodynamic Properties of IW-6463 in Healthy Elderly Subjects

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 20 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zagociguat (Primary)
Indications Alzheimer's disease; Dementia; Mitochondrial disorders
Focus Adverse reactions; Pharmacodynamics
Sponsors Cyclerion Therapeutics

Most Recent Events

22 Apr 2021 Results assessing safety, tolerability, pharmacokinetics, and central nervous system (CNS) activity of IW-6463 presented at the 73rd Annual Meeting of the American Academy of Neurology
14 Oct 2020 Results published in Cyclerion Therapeutics Media Release.
25 Aug 2020 According to a Cyclerion Therapeutics media release, top line data from this study are expected in September 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com